Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: The okayama lung cancer study group trial 1001

Journal of Thoracic Oncology

Volumn 10, Issue 3, 2015, Pages 486-491

  Ichihara, Eiki ^a,b   Hotta, Katsuyuki ^a   Nogami, Naoyuki ^c   Kuyama, Shoichi ^d   Kishino, Daizo ^e   Fujii, Masanori ^f   Kozuki, Toshiyuki ^c   Tabata, Masahiro ^a   Harada, Daijiro ^c,g   Chikamori, Kenichi ^e   Aoe, Keisuke ^e   Ueoka, Hiroshi ^e   Hosokawa, Shinobu ^h   Bessho, Akihiro ^h   Hisamoto Sato, Akiko ^a   Kubo, Toshio ^a   Oze, Isao ⁱ   Takigawa, Nagio ^j   Tanimoto, Mitsune ^a   Kiura, Katsuyuki ^a  

^a OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^d IWAKUNI NATIONAL HOSPITAL   (Japan)

^e NATIONAL SANYO HOSPITAL   (Japan)

^f Japanese Red Cross Kobe Hospital   (Japan)

^g Sumitomo Besshi Hospital   (Japan)

^h Japanese Red Cross Okayama Hospital   (Japan)

ⁱ AICHI CANCER CENTER HOSPITAL   (Japan)

^j KAWASAKI MEDICAL SCHOOL   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; COLON PERFORATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENE DELETION; GENE MUTATION; HUMAN; HYPERTENSION; MALE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; POINT MUTATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RASH; SURVIVAL RATE; SURVIVAL TIME; THROMBOEMBOLISM; VERY ELDERLY; ADENOCARCINOMA; CANCER GRADING; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CASE CONTROL STUDY; CLINICAL TRIAL; FOLLOW UP; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MUTATION; PATHOLOGY; PROSPECTIVE STUDY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; NEOPLASM STAGING; PROSPECTIVE STUDIES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE;

EID: 84938275519     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000434     Document Type: Article

References (26)

1. Lynch TJ, Bell DW, Sordella R, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004 350 2129 2139
2. Paez JG, Jänne PA, Lee JC, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004 304 1497 1500
3. Maemondo M, Inoue A, Kobayashi K, North-East Japan Study Group Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010 362 2380 2388
4. Mitsudomi T, Morita S, Yatabe Y, West Japan Oncology Group Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010 11 121 128
5. Zhou C, Wu YL, Chen G, Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011 12 735 742
6. Rosell R, Carcereny E, Gervais R, Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012 13 239 246
7. Sandler A, Gray R, Perry MC, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006 355 2542 2550
8. Ciardiello F, Caputo R, Damiano V, Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 2003 9 1546 1556
9. De Luca A, Carotenuto A, Rachiglio A, The role of the EGFR signaling in tumor microenvironment. J Cell Physiol 2008 214 559 567
10. Hirata A, Ogawa S, Kometani T, ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 2002 62 2554 2560
11. Petit AM, Rak J, Hung MC, Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997 151 1523 1530
12. Jung YD, Mansfield PF, Akagi M, Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur J Cancer 2002 38 1133 1140
13. Ciardiello F, Bianco R, Damiano V, Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 2000 6 3739 3747
14. Tonra JR, Deevi DS, Corcoran E, Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin Cancer Res 2006 12 7 Pt 1 2197 2207
15. Naumov GN, Nilsson MB, Cascone T, Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res 2009 15 3484 3494
16. Ichihara E, Ohashi K, Takigawa N, Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo. Cancer Res 2009 69 5091 5098
17. Nagai Y, Miyazawa H, Huqun, Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 2005 65 7276 7282
18. Kimura H, Fujiwara Y, Sone T, High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients. Cancer Sci 2006 97 642 648
19. Herbst RS, Ansari R, Bustin F, Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet 2011 377 1846 1854
20. Seto T, Kato T, Nishio M, Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol 2014 15 1236 1244
21. Hayakawa H, Ichihara E, Ohashi K, Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epidermal growth factor receptor-mutated lung cancer model. Cancer Sci 2013 104 1440 1446
22. Ichihara E, Hotta K, Takigawa N, Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations. Lung Cancer 2013 81 435 439
23. Carey KD, Garton AJ, Romero MS, Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res 2006 66 8163 8171
24. Davis MI, Hunt JP, Herrgard S, Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 2011 29 1046 1051
25. Mok TS, Wu YL, Thongprasert S, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009 361 947 957
26. Ramalingam SS, Dahlberg SE, Langer CJ, Eastern Cooperative Oncology Group Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008 26 60 65